| Rosenberg Health & Rehabilitation Center | |
| 1419 Mahlman St, Rosenberg, Texas 77471 | |
| (281) 342-0065 | |
| Name | Rosenberg Health & Rehabilitation Center |
|---|---|
| Location | 1419 Mahlman St, Rosenberg, Texas |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 142 |
| Occupancy Rate | 57.82% |
| Medicare ID (CCN) | 675046 |
| Legal Business Name | Rosenberg Snf Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1033167390 |
| Organization Name | ROSENBERG HEALTH & REHABILITATION CENTER, L.P. |
| Doing Business As | ROSENBERG HEALTH & REHABILITATION CENTER |
| Address | 1419 Mahlman Street, Rosenberg, TX 77471 |
| Phone Number | 281-342-0065 |
News Archive
Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory-grown, human airway cells that a condensed form of cigarette smoke triggers so-called "epigenetic" changes in the cells consistent with the earliest steps toward lung cancer development.
Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).
A study by researchers at Hospital for Special Surgery has provided the first evidence that the shape of a person's knee could be a factor in the decision of whether a patient should undergo anterior cruciate ligament (ACL) reconstruction after an ACL tear.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the acquisition of InferMed, a London-based clinical decision support (CDS) technology company.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
› Verified 9 days ago
| NPI Number | 1891021242 |
| Organization Name | HAMILTON COUNTY HOSPITAL DISTRICT |
| Doing Business As | ROSENBERG HEALTH & REHABILITATION CENTER |
| Address | 1419 Mahlmann St, Rosenberg, TX 77471 |
| Phone Number | 281-342-0065 |
News Archive
Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory-grown, human airway cells that a condensed form of cigarette smoke triggers so-called "epigenetic" changes in the cells consistent with the earliest steps toward lung cancer development.
Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).
A study by researchers at Hospital for Special Surgery has provided the first evidence that the shape of a person's knee could be a factor in the decision of whether a patient should undergo anterior cruciate ligament (ACL) reconstruction after an ACL tear.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the acquisition of InferMed, a London-based clinical decision support (CDS) technology company.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory-grown, human airway cells that a condensed form of cigarette smoke triggers so-called "epigenetic" changes in the cells consistent with the earliest steps toward lung cancer development.
Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).
A study by researchers at Hospital for Special Surgery has provided the first evidence that the shape of a person's knee could be a factor in the decision of whether a patient should undergo anterior cruciate ligament (ACL) reconstruction after an ACL tear.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the acquisition of InferMed, a London-based clinical decision support (CDS) technology company.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $149995 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 7.53 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.93 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 23.48 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.57 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.67 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 3.04 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 8.09 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 96.65 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 6.33 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 11.33 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.16 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 12.28 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.95 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 65.36 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 73.37 | 82.93 |
News Archive
Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory-grown, human airway cells that a condensed form of cigarette smoke triggers so-called "epigenetic" changes in the cells consistent with the earliest steps toward lung cancer development.
Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).
A study by researchers at Hospital for Special Surgery has provided the first evidence that the shape of a person's knee could be a factor in the decision of whether a patient should undergo anterior cruciate ligament (ACL) reconstruction after an ACL tear.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the acquisition of InferMed, a London-based clinical decision support (CDS) technology company.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
› Verified 9 days ago
Rosenberg Health & Rehabilitation Center Location: 1419 Mahlman St, Rosenberg, Texas 77471 Phone: (281) 342-0065 | |